SMT201700392T1 - Particelle simil-virali (vlp) di glicoproteina della rabbia - Google Patents

Particelle simil-virali (vlp) di glicoproteina della rabbia

Info

Publication number
SMT201700392T1
SMT201700392T1 SM20170392T SMT201700392T SMT201700392T1 SM T201700392 T1 SMT201700392 T1 SM T201700392T1 SM 20170392 T SM20170392 T SM 20170392T SM T201700392 T SMT201700392 T SM T201700392T SM T201700392 T1 SMT201700392 T1 SM T201700392T1
Authority
SM
San Marino
Prior art keywords
vlps
particles
rabies glycoprotein
glycoprotein virus
virus
Prior art date
Application number
SM20170392T
Other languages
English (en)
Italian (it)
Inventor
Gale Smith
Ye Liu
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of SMT201700392T1 publication Critical patent/SMT201700392T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SM20170392T 2010-11-05 2011-11-07 Particelle simil-virali (vlp) di glicoproteina della rabbia SMT201700392T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41076710P 2010-11-05 2010-11-05
PCT/US2011/059602 WO2012061815A2 (en) 2010-11-05 2011-11-07 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
EP11838942.8A EP2635257B1 (en) 2010-11-05 2011-11-07 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)

Publications (1)

Publication Number Publication Date
SMT201700392T1 true SMT201700392T1 (it) 2017-09-07

Family

ID=46025156

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20170392T SMT201700392T1 (it) 2010-11-05 2011-11-07 Particelle simil-virali (vlp) di glicoproteina della rabbia

Country Status (23)

Country Link
US (3) US9724405B2 (enExample)
EP (2) EP2635257B1 (enExample)
JP (2) JP6158088B2 (enExample)
KR (1) KR101847908B1 (enExample)
CN (2) CN109157658A (enExample)
AU (1) AU2011323090B2 (enExample)
BR (1) BR112013011194B1 (enExample)
CA (1) CA2817005C (enExample)
CY (1) CY1119284T1 (enExample)
DK (1) DK2635257T3 (enExample)
ES (1) ES2636965T3 (enExample)
HR (1) HRP20171213T1 (enExample)
HU (1) HUE034247T2 (enExample)
IL (1) IL226187B (enExample)
LT (1) LT2635257T (enExample)
MX (1) MX354750B (enExample)
PL (1) PL2635257T3 (enExample)
PT (1) PT2635257T (enExample)
RS (1) RS56157B1 (enExample)
SG (1) SG190140A1 (enExample)
SI (1) SI2635257T1 (enExample)
SM (1) SMT201700392T1 (enExample)
WO (1) WO2012061815A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin
WO2012061815A2 (en) * 2010-11-05 2012-05-10 Novavax Inc. RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
WO2012171104A1 (en) * 2011-06-13 2012-12-20 Medicago Inc. Rabies virus like particle production in plants
KR101479668B1 (ko) 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN103777021B (zh) * 2012-10-18 2016-03-02 辽宁成大生物股份有限公司 狂犬疫苗糖蛋白含量的检测方法
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
ES2975182T3 (es) 2017-03-06 2024-07-03 Guangzhou Realbenefitspot Pharmaceutical Co Ltd Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
CN118490817A (zh) * 2017-11-06 2024-08-16 英特维特国际股份有限公司 狂犬病毒疫苗
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
KR102077772B1 (ko) 2018-11-29 2020-02-17 주식회사 바이오앱 광견병 예방용 백신 조성물 및 이의 제조 방법
KR102211077B1 (ko) * 2019-01-16 2021-02-02 충남대학교 산학협력단 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN109959789B (zh) * 2019-04-12 2022-08-16 长春西诺生物科技有限公司 一种狂犬病毒抗体检测试纸及其制备方法与检测方法
CN110007080B (zh) * 2019-04-12 2022-09-23 长春西诺生物科技有限公司 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2023064931A1 (en) * 2021-10-15 2023-04-20 La Jolla Institute For Immunology Engineered rabies virus glycoprotein, compositions, and methods of use thereof
CN114272367B (zh) * 2021-12-03 2023-07-07 华东理工大学 一种口服狂犬病病毒样颗粒疫苗及其制备方法
KR102566969B1 (ko) 2021-12-14 2023-08-16 안희철 근거리 통신 과정에서 충전 가능한 모바일 단말
CN117867029B (zh) * 2023-12-29 2024-12-20 复百澳(苏州)生物医药科技有限公司 一种狂犬亚型假病毒的制备方法及应用
PE20251405A1 (es) 2024-07-18 2025-05-22 Farm Veterinarios S A C Variantes sinteticas de la glicoproteina g del virus de la rabia para la generacion de baculovirus pseudotipados y su uso en formulaciones vacunales anti-rabicas

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237686A1 (en) 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5667782A (en) 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6589533B1 (en) * 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
US6673601B1 (en) * 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20100167341A1 (en) 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
US8153115B2 (en) 2006-06-15 2012-04-10 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
EP2035565A4 (en) * 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
US8980281B2 (en) 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
TW200907058A (en) 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US20100330122A1 (en) * 2007-07-19 2010-12-30 Gale Smith VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS
KR100961280B1 (ko) * 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
WO2009153801A1 (en) 2008-06-17 2009-12-23 Manpreet Kaur Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof
US9296790B2 (en) * 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
ES2987238T3 (es) * 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
WO2012061815A2 (en) * 2010-11-05 2012-05-10 Novavax Inc. RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)

Also Published As

Publication number Publication date
EP2635257A2 (en) 2013-09-11
BR112013011194A2 (pt) 2017-06-27
SG190140A1 (en) 2013-06-28
EP2635257A4 (en) 2014-04-02
CN109157658A (zh) 2019-01-08
JP6195965B2 (ja) 2017-09-13
US10086065B2 (en) 2018-10-02
AU2011323090A1 (en) 2013-04-04
EP3246019A1 (en) 2017-11-22
JP2017035093A (ja) 2017-02-16
EP3246019B1 (en) 2021-03-03
IL226187B (en) 2018-04-30
CY1119284T1 (el) 2018-02-14
DK2635257T3 (en) 2017-09-04
CN103282023A (zh) 2013-09-04
HUE034247T2 (en) 2018-02-28
ES2636965T3 (es) 2017-10-10
US20190224307A1 (en) 2019-07-25
WO2012061815A2 (en) 2012-05-10
EP2635257B1 (en) 2017-07-05
CA2817005A1 (en) 2012-05-10
AU2011323090B2 (en) 2015-02-12
CA2817005C (en) 2018-09-11
MX2013005090A (es) 2013-10-25
MX354750B (es) 2018-03-20
JP2014500013A (ja) 2014-01-09
WO2012061815A3 (en) 2013-03-14
SI2635257T1 (en) 2018-01-31
CN103282023B (zh) 2018-09-21
HRP20171213T1 (hr) 2017-10-20
US9724405B2 (en) 2017-08-08
RU2013125695A (ru) 2014-12-10
BR112013011194B1 (pt) 2020-12-22
IL226187A0 (en) 2013-07-31
LT2635257T (lt) 2017-09-25
KR101847908B1 (ko) 2018-04-11
JP6158088B2 (ja) 2017-07-05
PT2635257T (pt) 2017-08-16
RS56157B1 (sr) 2017-11-30
US20180021428A1 (en) 2018-01-25
US20140178419A1 (en) 2014-06-26
PL2635257T3 (pl) 2017-10-31
KR20130111581A (ko) 2013-10-10

Similar Documents

Publication Publication Date Title
IL226187A0 (en) Virus-like glycoprotein particles
IL210215A0 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
ZA201200481B (en) Chimeric influenza virus-like particles comprising hemagglutinin
EP2536428A4 (en) UNIVERSAL INFLUENZA VACCINES WITH VIRUSIC PARTICLES
GB201005005D0 (en) New vaccine
ZA201404516B (en) Vaccines against hpv
ZA201403557B (en) Hpv chimaeric particle
EP2670843A1 (en) Multivalent vaccines for rabies virus and filoviruses
IL231132A0 (en) Viral cleaning methods
EP2538969A4 (en) VACCINES FROM POLYSACCHARIDE PARTICLES
AU2012307348A8 (en) Vaccine
ZA201403059B (en) Increasing virus-like particle yield in plants
EP2802349A4 (en) IMMUNOGENIC VLP CONTAINING L2 HPV AND COMPOSITIONS AND METHODS THEREOF
EP2707480A4 (en) PSEUDOVIRAL PARTICLES (VLPs) AND PREPARATION METHOD THEREOF
EP2519539A4 (en) METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
GB201001726D0 (en) Bunyavirus vaccine
SI2739725T1 (sl) Postopek za čiščenje od virusov-podobnih delcev
EP2632487A4 (en) VIRUS VACCINE AND MANUFACTURING METHOD THEREFOR
IL220941A0 (en) Method for producing recombinant virus
ZA201303361B (en) Process for extrusing particles
EP2572245A4 (en) PROCESS FOR PRODUCING STRUCTURED PARTICLES
HK1195787A (en) Virus-like particles and process for preparing same
HK1155480A (en) Influenza virus-like particles (vlps) comprising hemagglutinin
GB201013365D0 (en) Hypertension vaccine
AU2011900657A0 (en) Vaccine